Professor Limmroth discusses brain atrophy in multiple sclerosis
Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis' Gilenya® (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis (MS) - brain volume loss, lesion activity (measure by magnetic resonance imaging - MRI), relapse rates and disability progression.
